Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan

doi:10.3390/biology10040334

機構典藏 > College of Sciences > Graduate Institute & Department of Chemistry > Journal Article > Item 987654321/120757

Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/120757

Title:	Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan
Authors:	Chen, Yi-Wei;Lee, Yi-Yen;Lin, Chun-Fu;Pan, Po-Shen;Chen, Jen-Kun;Wang, Chun-Wei;Hsu, Shih-Ming;Kuo, Yu-Cheng;Lan, Tien-Li;Hsu, Sanford P. C.;Liang, Muh-Lii;Chen, Robert Hsin-Hung;Chang, Feng-Chi;Wu, Chih-Chun;Lin, Shih-Chieh;Liang, Hsiang-Kuang;Lee, Jia-Cheng;Chen, Shih-Kuan;Liu, Hong-Ming;Peir, Jinn-Jer;Lin, Ko-Han;Huang, Wen-Sheng;Chen, Kuan-Hsuan;Kang, Yu-Mei;Liou, Shueh-Chun;Wang, Chun-Chieh;Pai, Ping-Ching;Li, Chih-Wei;Chiek, Daniel Quah Song;Wong, Tai-Tong;Chiou, Shih-Hwa;Chao, Yee;Tanaka, Hiroki;Chou, Fong-In;Ono, Koji
Keywords:	BNCT;glioblastoma;T/N ratio;T/B ratio;radioresistance
Date:	2021-04-15
Issue Date:	2021-05-06 12:11:12 (UTC+8)
Publisher:	MDPI
Abstract:	Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and 18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of 18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan–Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival.
Relation:	Biology 10(4), 334
DOI:	10.3390/biology10040334
Appears in Collections:	[Graduate Institute & Department of Chemistry] Journal Article

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	102	View/Open

Loading...